Look up one drug

Ontario coverage, price, criteria word for word, Health Canada status and shortages for one product

Patient plan: look up a medication list

NETUPITANT & PALONOSETRON HYDROCHLORIDE

All products: Limited Use (codes 561, 562)

Other products in the same Health Canada class (A04A, A04AA) — coverage varies; not interchangeable

  • Granisetron (Kytril): limited Use 326, 454, Not a benefit
  • Ondansetron (Zofran ODT (Tablet)): limited Use 215, 216, 217, 218, 454, 696, Not a benefit
  • Ondansetron (Zofran): not a benefit
  • Nabilone (Cesamet): general benefit, Not a benefit
  • Aprepitant (Emend Tri-Pack): limited Use 452, 453

Akynzeo · DIN 02468735 · 300mg & 0.5mg · capsule

Limited Use — Reason for Use code 561, 562 requiredMarketed · checked 2026-09-18
StatusLimited Use — Reason for Use code 561, 562 required
Write on scriptLU code 561, 562 (patient must meet the criteria below)
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Ontario Limited Use criteria — code 561, 562
Reason for Use code 561 In combination with dexamethasone for once per-cycle treatment in adult patients for: - Prevention of acute and delayed nausea and vomting associated with highly emetogenic cancer chemotherapy (HEC). Highly emetogenic chemotherapy (HEC) regimens: - Cisplatin-based chemotherapy where a single daily dose is greater than or equal to 70mg per meter squared - Cisplatin and cyclophosphamide combinations where the single daily dose of cisplatin is greater than or equal to 50mg per meter squared - Non-cisplatin based highly emetogenic chemotherapy (such as those containing anthracycline greater than or equal to 60mg per meter squared plus cyclophosphamide). Dosage: Recommend Netupitant/Palonosetron 300mg/0.5mg orally on Day 1 approximately 1 hour prior to the start of each HEC. Coverage limit: LU Authorization Period: 1 year Reason for Use code 562 In combination with dexamethasone for once per-cycle treatment in adult patients for: - Prevention of acute nausea and vomiting associated with moderately emetogenic cancer therapy (MEC) that is uncontrolled by a 5-hydroxytryptamine-3 (5-HT3) receptor antagonist (RA) alone in a previous cycle. Dosage: Recommend Netupitant/Palonosetron 300mg/0.5mg orally on Day 1 approximately 1 hour prior to the start of each MEC cycle. Coverage limit: LU Authorization Period: 1 year
No interchangeable product listed in the Ontario extract
Akynzeo · DIN 02468735 Manufacturer: Knight Therapeutics Inc.; listing date 2019-06-28 Health Canada: Marketed since 2022-11-30 · brand AKYNZEO · ATC A04AA55 PALONOSETRON, COMBINATIONS · form Capsule · route Oral · ingredients PALONOSETRON (PALONOSETRON HYDROCHLORIDE) 0.5 MG, NETUPITANT 300 MG · company Knight therapeutics inc. · schedule Prescription
Check this DIN again · Health Canada product record

Akynzeo: Formulary list price $144.0075/unit (unit not stated in source; not the patient's cost)

Ministry pays: $144.0075 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=95721 · Verify on the e-Formulary ↗ (DIN 02468735)

Source record
DIN 02468735: Akynzeo Raw flags: sec12=Y, sec3=Y Item: 562200052; group id 669; item number 1659; lccId 00319; manufacturer id KNT Source form: Cap; strength: 300mg & 0.5mg Recorded listing: Limited Use: paid only with a Reason for Use code and the criteria below Source prices (unrounded): $144.0075; ministry $144.0075 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02468735 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=95721
Shortage status: no shortage or discontinuation reported (checked 2026-09-13T08:10:21.292534+00:00); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02468735
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Other drugs in the same formulary class (56:22 Antiemetics and Antinauseants) and how they are covered

Matched class: 56:22 Antiemetics and Antinauseants

Drug-class inventory only. Lists recorded Ontario formulary products, not every Canadian medication; does not recommend treatment. Covered without a code on the Ontario formulary: DOXYLAMINE SUCCINATE AND PYRIDOXINE HCL, MECLIZINE HCL Some products covered without a code (check the product listing): NABILONE 56:22 Antiemetics and Antinauseants

GRANISETRON HCL

· 4 products · Listed, not a benefit (1), Limited Use, codes 91, 92, 93, 326, 454 (3) · strengths: 1mg · Tab

ONDANSETRON HYDROCHLORIDE

· 54 products · Listed, not a benefit (5), Limited Use, codes 215, 216, 217, 218, 454, 696 (49) · strengths: 4mg, 8mg, 4mg/5mL · O/L, Tab

ONDANSETRON HCL DIHYDRATE

· 6 products · Off-Formulary Interchangeable, not an ODB benefit · strengths: 2mg/mL · Inj Sol-2mL Pk, Inj Sol-4mL Pk

NABILONE

· 10 products · Off-Formulary Interchangeable, not an ODB benefit (4), General benefit (6) · strengths: 0.25mg, 0.5mg, 1mg · Cap

APREPITANT

· 1 products · Limited Use, codes 452, 453 · strengths: 125mg & 80mg · Cap

DOXYLAMINE SUCCINATE AND PYRIDOXINE HCL

· 4 products · General benefit · strengths: 10mg & 10mg · SR Tab

MECLIZINE HCL

· 1 products · General benefit · strengths: 25mg · Tab

DIMENHYDRINATE

· 2 products · Limited Use, codes 481 · strengths: 50mg/mL · Inj Sol (with Preservative) Source: formulary-ed43-front-matter.txt Part V; ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26; class 56:22
Full class listing Related classes: 56:04 Antacids and Adsorbents, 56:08 Antidiarrhea Agents, 56:12 Cathartics, 56:16 Digestants, 56:40 Miscellaneous G.I. Drugs Same formulary class, not same indication: class membership alone does not establish equivalent uses.
What the Health Canada label says it is for
INDICATIONS AND CLINICAL USE Akynzeo® (netupitant/palonosetron) in combination with dexamethasone, is indicated for once- per-cycle treatment in adult patients for:  Prevention of acute and delayed nausea and vomiting associated with highly emetogenic cancer chemotherapy  Prevention of acute nausea and vomiting associated with moderately emetogenic cancer therapy that is uncontrolled by a 5-HT3 receptor antagonist alone Geriatrics (≥ 65 years of age): No dosage adjustment is required in patients ≥ 65 years of age and older. In general, use caution when dosing geriatric patients as they have a greater frequency of decreased hepatic, renal or cardiac function and concomitant disease or other drug therapy. Pediatrics (< 18 years of age): The safety and effectiveness of Akynzeo in patients below the age of 18 years have not been established. No data are available. Page 3 of 36 https://pdf.hres.ca/dpd_pm/00068269.PDF PM date: not printed or not captured Source product: AKYNZEO; DIN 02468735; fetched 2026-09-10 Product monograph posted by Health Canada; excerpt for lookup only.